Tardive dyskinesia in elderly patients: An update

Journal of the American Medical Directors Association

Volumn 3, Issue 3, 2002, Pages 152-161

  Goldberg, Richard J ^a,b,c  

^a BROWN UNIVERSITY   (United States)

^b MIRIAM HOSPITAL   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

Author keywords

Elderly; Novel antipsychotics; Side effects; Tardive dyskinesia

Indexed keywords

ALPHA TOCOPHEROL; AMANTADINE; ANTIOXIDANT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; LITHIUM; MELATONIN; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PYRIDOXINE; QUETIAPINE; RISPERIDONE;

AKATHISIA; ANTICHOLINERGIC EFFECT; BEHAVIOR DISORDER; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DYSTONIA; ELDERLY CARE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPOTENSION; NEUROLOGIC DISEASE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; TARDIVE DYSKINESIA; VISUAL IMPAIRMENT; XEROSTOMIA;

EID: 23644442082     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/S1525-8610(04)70458-2     Document Type: Review

References (113)

1. Kane JM, Marder SR. Psychopharmacologic treatment of schizophrenia. Schizophr Bull 1993;19:287-302.
2. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs Schizophr Res 1995;35:S61-S66.
3. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry 1999;60[suppl]:29-41.
4. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999;7:70-76.
5. Klawans HL, Barr A. Prevalence of spontaneous lingual-facial-buccal dyskinesias in the elderly. Neurology 1982;32:558-559.
6. Waddington JL. Tardive dyskinesia in schizophrenia and other disorders: Association with aging, cognitive dysfunction, and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharmacol 1987;2:11-22.
7. Barnes TR. The present status of tardive dyskinesia and akathisia in the treatment of schizophrenia. Psychiatr Dev 1987;4:301-219.
8. Kane JM, Woerner M, Lieberman JA. Tardive dyskinesia: Prevalence, incidence, and risk factors. Psychopharmacology 1988;2:72-78.
9. Crane GE. Persistent dyskinesia. Br J Psychiatry 1973;122:395-405.
10. Barnes TR, Braude W. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42:874-878.
11. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. J Clin Psychopharmacol 1988;8:21-26.
12. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: Late-onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
13. Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121:2053-2066.
14. Klawans HL Jr, Ilahi MM, Shenker D. Theoretical implications of the use of L-dopa in parkinsonism. Acta Neurol Scand 1970;46:409-441.
15. Thaker GK, Tamminga CA, Alphs LD, et al. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Arch Gen Psychiatry 1987;44:522-529.
16. Andersson U, Haggstrom JE, Levin ED, et al. Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Move Disord 1989;4:37-46.
17. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia: A practical GABA-mimetic strategy. Am J Psychiatry 1990;147:445-451.
18. Pai BN, Janakiramaiah N, Gangadhar BN, Ravindranath V. Depletion of glutathione and enhanced lipid peroxidation in the CSF of acute psychotics following haloperidol administration. Biol Psychiatry 1994;36:489-491.
19. Crossman AE. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: Implications for future strategies in treatment. Move Disord 1990;5:100-108.
20. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-289.
21. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609.
22. Gardos G, Cole JO, Haskell D, et al. The natural history of tardive dyskinesia. J Clin Psychopharmacol 1998;8:31S-37S.
23. Bergen JA, Eyland EA, Campbell JA, et al. The course of tardive dyskinesia in patients on long-term neuroleptics. Br J Psychiatry 1989;154:523-528.
24. Gardos G, Casey DE, Cole JO, et al. Ten-year outcome of tardive dyskinesia. Am J Psychiatry 1994;151:836-841.
25. Smith JM, Baldessarini RJ. Changes in prevalence, severity and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 1980;37:1368-1373.
26. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999;35:S61-S66.
27. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull 1992;18:701-715.
28. Glazer WM, Morgenstern H, Schooler N, et al. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry 1990;157:585-592.
29. Glazer WM, Morgenstern H, Doucette JT. The prediction of chronic persistent versus intermittent tardive dyskinesia: A retrospective follow-up study. Br J Psychiatry 1991;158:822-828.
30. Yassa R, Nair V, Schwartz G. Early versus late onset psychosis and tardive dyskinesia. Biol Psychiatry 1986;21:1291-1297.
31. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406.
32. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.
33. Barnes TRE, Liddle PF. Tardive dyskinesia: Implications for schizophrenia?. In: Schiff AA, Roth M, Freeman HL, eds. Schizophrenia: New Pharmacological and Clinical Development. London: Royal Society of Medicine Services, 1985:81-87.
34. Jeste DV, Karson CN, Iager AC, et al. Association of abnormal involuntary movements and negative symptoms. Psychopharmacol Bull 1984;20:380-381.
35. Casey DE. Affective disorders and tardive dyskinesia. Encéphale 1988;14:221-226.
36. Rosenbaum AH, Niven RG, Hanson NP, Swanson DW. Tardive dyskinesia: Relationship with primary affective disorder. Dis Nerv Syst 1977;38:423-426.
37. Rush M, Diamond F, Alpert M. Depression as a risk factor in tardive dyskinesia. Biol Psychiatry 1982;17:387-392.
38. Richardson MA, Pass R, Bregman Z, Craig TJ. Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacol Bull 1985;21:130-135.
39. Wegner JT, Catalano F, Gibralter J, Kane JM. Schizophrenics with tardive dyskinesia: Neuropsychological deficit and family psychopathology. Arch Gen Psychiatry 1985;42:860-865.
40. Yassa R, Nair NP, Iskander H, Schwartz G. Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990;147:1156-1163.
41. Caligiuri MP, Lacro JP, Rockwell E, et al. Incidence and risk factors for severe tardive dyskinesia in older patients. Br J Psychiatry 1997;171:148-153.
42. Jeste DV, Wyatt RJ. Therapeutic strategies against tardive dyskinesia: Two decades of experience. Arch Gen Psychiatry 1982;39:803-816.
43. Richelson E. Preclinical pharmacology of neuroleptics: Focus on new generation compounds. J Clin Psychiatry 1996;57[suppl]:4-11.
44. Woerner MG, Kane JM, Lieberman JA, et al. The prevalence of tardive dyskinesia. J Clin Psychopharmacol 1991;11:34-42.
45. Harris MJ, Panton D, Caligiuri MP, et al. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. Psychopharmacol Bull 1992;28:87-92.
46. Byne W, White L, Parella M, et al. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: Prevalence and association with cognitive impairment. Int J Geriatr Psychiatry 1998;13:473-479.
47. Kane JM. Prospective study of tardive dyskinesia in the elderly. In: Abstracts of The American Psychiatric Association 152nd Annual Meeting: May 15-20, 1999, Washington DC. Abstract 31C.
48. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. Am J Psychiatry 1998;155:1521-1528.
49. Waddington JL. Subgroups in schizophrenia. Lancet 1985;1:1502-1503.
50. Munetz MR, Schulz SC. Screening for tardive dyskinesia. J Clin Psychiatry 1986;47:75-77.
51. Hyde T, Hotson JR, Kleinman JE. Differential diagnosis of choreiform tardive dyskinesia. J Neuropsychiatry 1991;3:255-268.
52. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-487.
53. Stimmel GL. Tardive dyskinesia with low-dose, short-term neuroleptic therapy. Am J Hosp Pharm 1976;33:961-963.
54. Guy W. Abnormal Involuntary Movement Scale. In: ECDEU Assessment Manual for Psychopharmacology, Revised. DHS Publication No. (ADM) 91-338. Rockville, MD: National Institute of Mental Health, Psychopharmacology Research Branch, 1976.
55. Awouters F, Niemegeers CJE, Janssen PA. Tardive dyskinesia: Etiological and therapeutic aspects. Pharmacopsychiatry 1990;23:33-37.
56. Diederich NJ, Goetz CG. Drug-induced movement disorders. Neurol Clin 1998;16:125-139.
57. Brown K, Reid A, White T, et al. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 1998;43:863-867.
58. Ghadirian AM, Annable L, Belanger MC, Chouinard G. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 1996;57:22-28.
59. Jeste DV, Wyatt RJ. In search of treatment for tardive dyskinesia: Review of the literature. Schizophr Bull 1979;5:251-293.
60. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: A review of the literature. Arch Gen Psychiatry 1995;52:173-188.
61. Gardos G, Cole JO, Rapkin RM, et al. Anticholinergic challenge and neuroleptic withdrawal: Changes in dyskinesia and symptom measures. Arch Gen Psychiatry 1984;41:1030-1035.
62. Glazer WM, Bowers MB Jr, Charney DS, Heninger GR. The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry 1989;26:224-233.
63. Dixon L, Thaker G, Conley R, et al. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res 1993;10:267-271.
64. Schooler NR, Keith SJ, Severe JB, Matthews S. Acute treatment response and short term outcome in schizophrenia: First results of the NIMH Treatment Strategies in Schizophrenia Study. Psychopharmacol Bull 1989;25:331-335.
65. Casey DE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res 1991;4:109-120.
66. Harris MJ, Heaton RK, Schalz A, et al. Neuroleptic dose reduction in older psychotic patients. Schizophr Res 1997;27:241-248.
67. Jeste DV, Potkin SG, Sinha S, et al. Tardive dyskinesia: Reversible and persistent. Arch Gen Psychiatry 1979;36:585-590.
68. van Harten PN, Hoek HW, Matroos GE, et al. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry 1998;155:565-567.
69. Wilson JG, Pinkerton A, Miller MJ, et al. Tardive dyskinesia in elderly patients treated with haloperidol, risperidone and olanzapine. In: Abstract of The American Psychiatric Association 152nd Annual Meeting; May 15-20, 1999, Washington DC. Abstract NR690.
70. Jeste DV, Lacro JP, Bailey A, et al. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999;47:716-719.
71. Deleted in proof.
72. Lieberman J, Johns C, Cooper T, et al. Clozapine pharmacology and tardive dyskinesia. Psychopharmacology 1989;99:S54-S59.
73. Casey DE. Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia. J Clin Psychiatry 1998;59[suppl]:31-37.
74. Sweet RA, Pollock BG. New atypical antipsychotics: Experience and utility in the elderly. Drugs Aging 1998;12:115-127.
75. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
76. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
77. Peuskens J, and the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726.
78. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57-73.
79. Berman I, Merson A, Rachov-Pavlov J, et al. Risperidone in elderly schizophrenic patients: An open-label trial. Am J Geriatr Psychiatry 1996;4:173-179.
80. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: A clinical experience. Int Psychogeriatr 1997;9:65-68.
81. Zarate CA Jr, Baldessarini RJ, Siegel AJ, et al. Risperidone in the elderly: A pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-317.
82. Madhusoodanan S, Brecher M, Brenner R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Am J Geriatr Psychiatry 1999;7:132-138.
83. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-115.
84. Davidson M, Harvey PD, Vervarcke J, et al. A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. Int J Geriatr Psychiatry 2000;15:506-514.
85. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999;53:946-955.
86. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: A clinical experience. Int Psychogeriatr 1997;9:65-68.
87. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155.
88. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
89. Beasley CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137.
90. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
91. Kumar V, Brecher M. Psychopharmacology of atypical antipsychotics and clinical outcomes in elderly patients. J Clin Psychiatry 1999;60[suppl]:5-9.
92. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
93. Arvanitis AL, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246.
94. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997;54:549-557.
95. McManus DQ, Arvanitis AL, Kowalcyk BB. Quetiapine, a novel antipsychotic: Experience in elderly patients with psychotic disorders. Seroquel Trial 48 Study Group. J Clin Psychiatry 1999;60:292-298.
96. Lieberman JA, Lesser M, Johns C, et al. Pharmacological studies of tardive dyskinesia. J Clin Psychopharmacol 1988;8:57-63.
97. Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol. 1988;8:38-48.
98. Glazer WM, Hafez HM. A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 1990;3:315-320.
99. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317-320.
100. Tamminga CA, Thaker GK, Moran M, et al. Clozapine in tardive dyskinesia: Observations from human and animal model studies. J Clin Psychiatry 1994;55:102-106.
101. Kopala LC, Honer WG. Schizophrenia and severe tardive dyskinesia responsive to risperidone. J Clin Psychopharmacol 1994;14-430-431.
102. Chouinard G. Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 1995;15:36-44.
103. Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Am J Psychiatry 1993;150:1405-1407.
104. Hollister LE, and Trevino ES. Calcium channel blockers in psychiatric disorders: A review of the literature. Can J Psychiatry 1999;44:658-664.
105. Thaker GK, Nguyen JA, Strauss ME, et al. Clonazepam treatment of tardive dyskinesia; A practical GABAmimetic strategy. Am J Psychiatry 1990;147:445-151.
106. Jackson IV, Nuttall EA, Perez-Cruet J. Treatment of tardive dyskinesia with lecithin. Am J Psychiatry 1979;136:1458-1460.
107. Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: Double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511-1514.
108. Shamir E, Barak Y, Shalman I, et al. Melatonin treatment for tardive dyskinesia: A double-blind placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049-1052.
109. Angus S, Sugars J, Boltezar R, et al. A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17:88-91.
110. Ludatscher JI. Stable remission of tardive dyskinesia by L-dopa. J Clin Psychopharmacol 1989;9:39-41.
111. Sirota P, Mosheva T, Shabtay H, et al. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry 2000;157:287-289.
112. Ondo WG, Hanna PA, Jankovic J. tetrabenzine treatment for tardive dyskinesia: Assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-1281.
113. Freeman-Smith E, Steele TE. Evoking tardive dyskinesia by anticholinergic challenge. Am J Psychiatry 1981;138:121-122.